{"id":30575,"date":"2014-09-08T08:30:50","date_gmt":"2014-09-08T12:30:50","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=30575"},"modified":"2014-09-08T08:30:50","modified_gmt":"2014-09-08T12:30:50","slug":"biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575","title":{"rendered":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 According to reports, <strong>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) <\/strong>recently <a href=\"http:\/\/www.benzinga.com\/news\/14\/09\/4830165\/biocryst-pharmaceuticals-inc-announces-rapivab-trial-results-for-the-treatment-of\" target=\"_blank\">announced<\/a> the trial results of peramivir injection (RAPIVAB). It is a neuraminidase inhibitor for the treatment of influenza. BCRX finished the study some time back, and it decided to reveal the final trial results on the special occasion of ICAAC (the Inter-Science Conference on Antimicrobial Agents &amp; Chemotherapy) which was held in Washington, D.C. The conference started on September 5, 2014 and will go on till September 9, 2014.<\/p>\n<p style=\"text-align: justify;\"><strong>Insights of results: <\/strong><\/p>\n<p style=\"text-align: justify;\">As per the clinical trial results achieved by the BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), peramivir is probably the first NAI (neuraminidase inhibitor) which is quite effective and safe for patients as a single-dose therapy. This treatment is like a boon for those patients who are suffering from influenza. The complete information about the treatment and its consequences were revealed by none other than Richard Whitley, M.D, University of Alabama. He said that researchers conducted two random placebo-controlled trials and found that just one dose of peramivir was enough to administer parenterally alleviated flu symptoms. It could also reduce viral shedding and fever faster than placebo.<\/p>\n<p style=\"text-align: justify;\">The study confirmed that a single dose of intramuscular (I.M.) peramivir was effective, well-tolerated and safe. It could easily reduce the duration of viral shedding and clinical symptoms in the entire participant who had uncomplicated influenza. According to results, the average time of alleviation of influenza symptoms after peramivir 300 mg treatment was around 113.2 hours. It was lesser than the 134.8 hours taken for placebo. As soon as the patients were given the peramivir treatment, the Influenza viral shedding started decreasing within initial 48 hours. There was hardly any chance after the treatment when researchers failed to recognize the susceptibility to NAIs. The entire treatment proved to be very effective and useful. The team of researchers involved in this study looked quite hopeful for further advancements in the other parameters of the results.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 According to reports, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) recently announced the trial results of peramivir injection (RAPIVAB). It is a neuraminidase [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":16634,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8829,2868,2869,8830],"stock_ticker":[],"class_list":["post-30575","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-biocryst-pharmaceuticals-inc","tag-biocryst-pharmaceuticals-inc-nasdaqbcrx","tag-nasdaqbcrx","tag-richard-whitley","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 According to reports, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) recently announced the trial results of peramivir injection (RAPIVAB). It is a neuraminidase [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-08T12:30:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"294\" \/>\n\t<meta property=\"og:image:height\" content=\"220\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting\",\"datePublished\":\"2014-09-08T12:30:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg\",\"keywords\":[\"BioCryst Pharmaceuticals Inc.\",\"BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)\",\"NASDAQ:BCRX\",\"Richard Whitley\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\",\"name\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg\",\"datePublished\":\"2014-09-08T12:30:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg\",\"width\":294,\"height\":220},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575","og_locale":"en_US","og_type":"article","og_title":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting - Wall Street PR","og_description":"Boston, MA 09\/08\/2014 (wallstreetpr) \u2013 According to reports, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) recently announced the trial results of peramivir injection (RAPIVAB). It is a neuraminidase [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-08T12:30:50+00:00","og_image":[{"width":294,"height":220,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting","datePublished":"2014-09-08T12:30:50+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg","keywords":["BioCryst Pharmaceuticals Inc.","BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)","NASDAQ:BCRX","Richard Whitley"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575","url":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575","name":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg","datePublished":"2014-09-08T12:30:50+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/biocryst-pharmaceuticals-logo.jpg","width":294,"height":220},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-reports-rapivab-trial-results-at-the-icaac-2014-meeting-30575#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reports RAPIVAB Trial Results At The ICAAC 2014 Meeting"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=30575"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30575\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16634"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=30575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=30575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=30575"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=30575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}